AI-generated content for informational purposes only. Not financial advice. Always do your own research.

Over

Mondiaal medisch productiebedrijf dat essentiële therapieën biedt voor nierziekten, ziekenhuiszorg en chirurgische ingrepen. Meer dan 85 jaar innovatie in de gezondheidszorg.

Aandelen vergrijzende bevolking

Baxter biedt essentiële therapieën voor nierziekten, ziekenhuiszorg en chirurgische procedures, met meer dan 85 jaar gezondheidsinnovatie ten dienste van verouderende patiëntenpopulaties.

Key Financials BAX

Prijs $19.79
Wijziging (1D) +5.77%
Wijziging (30D) +3.56%
Wijziging (60D) +11.37%
Wijziging (90D) -14.51%
Wijziging (180D) -35.28%
Wijziging (1Y) -34.66%
Wijziging (5Y) -74.30%
P/E-verhouding 4.95
EPS (TTM) $4.00
52-weekse bandbreedte $17.40 — $37.74
50-daags MA $19.74
Volume 15.81M

Data updated Feb 15 · Source: Twelve Data

3.4
1 reviews
Demographic Exposure
3.8
Regulatory Risk
3
Growth Potential
2.5
Dividend Reliability
2
Financial Stability
1.8
Claude Opus 4.6
AI Review
3.4/5

Baxter International, a major medical products and renal care company, presents a complex investment case. The stock has suffered a dramatic decline"down 74% over five years and 35% over the past year"reflecting significant operational challenges, debt concerns from the Hill-Rom acquisition, and the recent divestiture of its kidney care segment (Vantive). The remarkably low P/E of 4.95 with EPS of $4.00 suggests either deep value or earnings that may not be sustainable in their current form post-restructuring.

Bull case: Baxter's core hospital products and medication delivery businesses serve essential healthcare needs. The aging population thesis remains intact as elderly patients disproportionately consume hospital supplies, IV solutions, and infusion therapies. At under $20, much bad news appears priced in, and recent 30/60-day momentum suggests stabilization.

Bear case: Heavy debt load, ongoing restructuring risk, and the separation from its kidney care business removes a key aging-population growth driver. The 5-year destruction of shareholder value raises governance concerns. Trading near 52-week lows with the 180-day decline of 35% signals persistent institutional selling.

Baxter offers turnaround potential but carries substantial execution risk.

Demographic Exposure
3.8
Regulatory Risk
3
Growth Potential
2.5
Dividend Reliability
2
Financial Stability
1.8
Feb 15, 2026
Baxter International Screenshot

Added: Feb 15, 2026

baxter.com

Latest from Otrai